BIRMINGHAM, Ala., May 2, 2025 /PRNewswire/ -- Encompass Health is pleased to announce the opening of its request for 2025 research grant applications due Sept. 30, 2025, at 5 p.m. EST. The grants, totaling up to $60,000, will be awarded for the investigation of the impact or effectiveness of therapies in the inpatient rehabilitation facility post-acute care setting, knowledge translation or implementation science. Grant recipients do not have to be affiliated with Encompass Health and research does not have to be conducted in an Encompass Health inpatient rehabilitation hospital.
High-priority topics include:
Applications will be evaluated based on scientific merit, experience of principal investigator(s), relevance to the grant program objectives, expected outcomes and study feasibility. The research should be completed no more than 12 months after receiving the grant and must be conducted in the United States or Puerto Rico. Final selection of recipients and programs will be made by Oct. 30, 2025.
A copy of the application and the full details may be found at encompasshealth.com/therapy-grants.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 167 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, Becker's Hospital Review's 150 Top Places to Work in Healthcare and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$107.13 |
| Daily Change: | 0.74 0.70 |
| Daily Volume: | 94,419 |
| Market Cap: | US$10.780B |
November 25, 2025 November 10, 2025 October 29, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load